Cinnarizine
- Atc Codes:N07CA02
- CAS Codes:298-57-7
- PHARMGKB ID:298-57-7
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Pericephal; Belgium: Cinnarizine, Stugeron; Bulgaria: Cinnarizin, Cinnarizine, Stugeron; Cyprus: Cinnaron; Czech Republic: Cinarizin, Cinnabene, Stugeron; Denmark: Sepan; Estonia: Cinnaron, Stugeron; Greece: Cinnarizine, Stugeron; Hungary: Stugeron; Ireland: Nagerine, Stugeron; Italy: Cinazyn, Stugeron, Toliman; Latvia: Cinnarizin, Stugeron; Lithuania: Cinnarizin, Stugeron; Luxembourg: Cinnarizine, Stugeron; Malta: Stugeron; Netherlands: Cinnarizine; Poland: Cinnarizinum, Stugeron; Portugal: Cinarizina, Cinon Forte, Stugeron; Romania: Cinarizin, Cinarizina, Stugeron; Slovakia: Cinarizin, Cinnabene, Stugeron; Slovenia: Cinarizin, Stugeron; Spain: Cinarizina, Stugeron; UK: Stugeron.
Latin America
Argentina: Cinarizina, Dismaren, Fabracin, Folcodal, Natropas, Stugeron; Brazil: Antigeron, Cinarizina, Civertim, Cronogeron, Ductogeron, Fluxon, Labigeron, Stugeron, Vertigeron, Verzum; Mexico: Bulasan, Ceretec, Cinarizina, Cisaken, Dilateron-F, Dilper-Ina, Karilex, Oblant, Reynaven, Stugeron, Venoxil, Winpar.
Drug combinations
Cinnarizine and Dimenhydrinate
Cinnarizine and Domperidone
Cinnarizine and Ergoloid Mesylates
Cinnarizine and Vincamine
Chemistry
Cinnarizine: C~26~H~28~N~2~. Mw: 368.51. (1) Piperazine, 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-; (2) 1-Cinnamyl-4-(diphenylmethyl)piperazine. CAS-298-57-7 (1962).
Pharmacologic Category
Anti-Dementia Agents; Vasoactive agents. Anti-Allergic Agent; Histamine H~1~ Antagonist. Calcium Channel Blocker. Anti-Emetic and Anti-Vertigo Preparation. (ATC-Code: N07CA02).
Mechanism of action
Non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents, including histamine. Also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarized cells, thereby reducing the availability of free Ca^2+^ ions for the induction and maintenance of contraction.
Therapeutic use
Vestibular disorders such as vertigo, tinnitus, nausea and vomiting, as seen in Meniere’s disease. Also effective in the control of motion sickness.
Pregnancy and lactiation implications
Safety in human pregnancy not established, although studies in animals have not demonstrated teratogenic effects. Use not recommended in pregnant or nursing mothers.
Unlabeled use
Contraindications
Hypersensitivity to cinarizine or any component of the formulation.
Warnings and precautions
May cause epigastric discomfort. Should only be administered in Parkinson’s disease if advantages outweigh possible risks of aggravating this disease. Because of its antihistamine effect, cinnarizine may prevent an otherwise positive reaction to dermal reactivity indicators if used within 4 days prior to testing. Use should be avoided in porphyria. Contains lactose and sucrose (use should be avoided in rare hereditary problems of fructose or galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).